Topic Listing for Human Genome Sciences

Abthrax Abthrax Raxibacumab
Address Principal Executive Offices Zip Code Adjustments Corporate Transactions Changes Common Stock
Administration Administration Eligibility
Aggregated Option Exercises Last Values End Agreement Novartis
Agreements Glaxosmithkline Formerly Smithkline Beecham Corporation Albuferon
Albuferon Albinterferon Alfa Albuferon Albinterferon Alfa-2b
Albumin Fusion Protein Drugs Albumin Fusion Technology
Albumin-fusion Technology Amendment Termination
Amendments Annex
Annual Report Pursuant Securities Exchange Act 1934 Annual Review
Antibodies Peptides Appendix Certificate Amendment Restated Incorporation Fifth Human Genome
Audit Committee Report Audit Fees
Audit-related Fees Bacillus Anthracis
Base Salary Basis Competition
Because Clinical Trials Products Expensive Protracted Outcome Uncertain Because Currently Mid-stage Development Cannot Certain Develop Business
Because Currently Only Limited Marketing Capability Unable Commercialize Because Depend Collaboration Partners Revenue Not Become Profitable
Because Depend Parties Conduct Some Laboratory Testing Human Because Issued Patents Not Fully Protect Discoveries Competitors
Because Limited Experience Developing Commercializing Products Unsuccessful Efforts Because Limited Resources Discovering Developing New Early Stage
Because Neither Nor Collaboration Partners Received Marketing Approval Because Stock Price Been Likely Continue Volatile Market
Because Subject Environmental Health Safety Laws Unable Conduct Because Subject Extensive Changing Government Regulatory Requirements Unable
Because Substantial Indebtedness Unable Adjust Strategy Meet Changing Cambridge Antibody Technology Cat
Cash Bonus Cash Incentive Awards
Ccr5 Receptor Antibodies Certificate Incorporation Bylaws Rights Plan Discourage Acquisition Proposals
Certification Principal Executive Officer Pursuant Usc 1350 906 Certification Principal Financial Officer Pursuant Usc 1350 906
Changes Internal Control Chief Executive Officers Compensation
Clinical Programs Clinical Testing
Code Ethics Business Conduct Collaboration Reimbursements Respect Novartis Gsk
Collaboration Reimbursements Respect Novartis Gsk Cogenesys Collaborators Pursues Product Competes Products Conflict Interest Not
Compensation Committee Compensation Committee Interlocks Insider Participation
Compensation Committee Report Compensation Committee Report Executive
Compensation Directors Compensation Discussion Analysis
Compensation Elements Compensation Newly Hired Executive Officers
Competition Competitors Substantially Greater Capabilities Resources Able Develop Commercialize
Compliance Exchange Act Composition
Consent Ernst Young Llp Independent Registered Public Accounting Consolidated Statements Operations
Continually Evaluating Business Strategy Modify Light Developments Other Corautus
Corporate Governance Guidelines Current Board Structure Proposed Declassification
Darapladib Darapladib Gsk480848
Diadexus Director Compensation
Directors Whose Term Expire 2007 Annual Meeting Directors Whose Term Expire 2008 Annual Meeting
Directors Whose Term Expire 2009 Annual Meeting Directors Whose Term Expire 2010 Annual Meeting 2009
Disclosure Controls Procedures Documents Incorporated Reference
Drug Development Dyax
Eligibility Participate Employee Stock Purchase Plan
Employees Employment Agreements Termination Change Control Arrangements
Entered Facility Lease Arrangement Not Required Reflected Balance Equity Compensation Plan Information
Espp Option Shares Table Employee Stock Purchase Plan Exact Name Registrant
Executive Compensation Executive Severance Plan
Face Risks Connection Abthrax Product Addition Generally Associated Federal Income Tax Consequences
Financial Market Risks Foreign Regulation
Form 10-k Fox Chase Cancer Center
Gene Protein Discovery Technology Gene Protein Human Antibody Technology
Gene Therapy Genentech
General Genomics-derived Human Monoclonal Antibody Drugs
Genomics-derived Small Molecule Drugs Glaxosmithkline
Government Agreement Government Regulation
Gsk626616 Gsk649868
Gsk716155 Albumin-glucagon-like Peptide Health Care System Reimbursement Policies Change Prices Potential
Human Antibody Discovery Development Human Antibody Technology
Human Gene Therapeutic Consortium Human Genome Sciences Inc
Iap Inhibitors Identification Executive Officers
Important Notice Regarding Availability Proxy Materials 2008 Annual Important Notice Regarding Availability Proxy Materials 2009 Annual
Incentive Stock Options Index Consolidated Financial Statements
Information Regarding Board Directors Certain Committees Insurance Policies Expensive Protect Only Some Business Risks
Intellectual Property Risks Kirin
Late-stage Products Lead Products
Legal Proceedings License Agreement Manufacturing Services Cogenesys
License Agreement Manufacturing Services Teva Biopharmaceuticals Usa Inc Long-term Investments Unrealized Losses
Lose Unable Attract Key Management Other Personnel Experience Lymphostat-b
Lymphostat-b Belimumab Management Report Internal Control Over Financial Reporting
Manufacturing Marketing
Marketing Approvals Medarex
Medimmune Meetings
Merck Kgaa Monogram Biosciences
Negative Public Opinion Increased Regulatory Scrutiny Gene Therapy New Plan Benefits Table
Nominations Process Nominees Director Three-year Term Expiring 2009 Annual Meeting
Nominees Director Three-year Term Expiring 2010 Annual Meeting Nominees Director Three-year Term Expiring 2011 Annual Meeting
Non-employee Director Options Nonqualified Stock Options
Novartis Number Shares
Off-balance Sheet Arrangements Oncology Products
Option Exercises Stock Vested Other
Other Collaboration Agreements Related 1996 Gsk Agreement Other Considerations
Other Fees Other Matters
Other Regulation Others Patent Applications Obtain Patents Similar Ours Then
Overview Part
Patent Applications Not Result Issued Patents Competitors Obtain Patent Laws Interpretation Change Competitors Able Develop Commercialize
Patents Proprietary Rights Performance Graph
Perquisites Other Personal Benefits Philosophy Objectives
Plan Benefits Possible Pricing Restrictions
Pre-approval Non-audit Services Preclinical Programs
Preclinical Testing Procedures Approval Related Person Transactions
Process Development Manufacturing Alliances Product Collaborations
Product Collaborations Agreements Product Development Risks
Products Products Gsk Pipeline
Properties Proposal Amend Restated Certificate Incorporation Fifth Declassify Board
Proposal Approval Amended Restated Stock Incentive Plan Proposal Approval Amendment Restatement Employee Stock Purchase Plan
Proposal Approval Employee Stock Purchase Plan Proposal Election Directors Whose Term Expire 2009
Proposal Election Directors Whose Term Expire 2010 Proposal Election Directors Whose Term Expire 2011
Proposal Ratification Independent Registered Public Accounting Firm Proposals 2007 Annual Meeting
Proposals 2008 Annual Meeting Proposals 2009 Annual Meeting
Proposals 2010 Annual Meeting Purchases Common Stock Espp
Purpose Quorum Voting Requirements
Reasons Proposed Declassification Regulatory Risks
Relacatib Gsk462795 Rely Collaboration Partners Seek Patent Protection Products They
Report Independent Registered Public Accounting Firm Internal Control Research Development
Research Development Capabilities Research Technology Collaborations
Resources Authority Revocation Proxies
Risk Collaboration Relationships Strategic Acquisitions Risks Collaboration Relationships Strategic Acquisitions
Safe Harbor Statement Private Securities Litigation Reform Act Sanofi-synthelabo
Schedule 14a Rule 14a-101 Schering-plough
Setting Executive Compensation Signatures
Solicitation Sources Supply
Stock Appreciation Rights Stock Awards
Stock Incentive Awards Stock Options
Stock Ownership Retention Guidelines Non-employee Directors Stockholder Communications Board Directors
Strategic Collaborations Strategy
Subsidiaries Summary Stock Incentive Plan Proposed Amended Restated
Syncria Albiglutide Takeda
Tax Accounting Implications Tax Aspects
Tax Fees Tax Implications
Technology Collaborations Term Plan
Termination Change Control Termination Without Change Control
Timing Annual Awards Trail Receptor Antibodies
Trail Receptor Antibody Transgene
Types Awards Unable Protect Trade Secrets Others Able Compete Effectively
Unable Successfully Establish Manufacturing Capability Obtain Required Quantities United States Government
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki